BiotechTube

lenvatinib + pembrolizumab + saline placebo

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Carcinoma, Hepatocellular

Conditions

Carcinoma, Hepatocellular

Trial Timeline

Dec 31, 2018 → Sep 24, 2024

NCT ID
NCT03713593

About lenvatinib + pembrolizumab + saline placebo

lenvatinib + pembrolizumab + saline placebo is a phase 3 stage product being developed by Eisai for Carcinoma, Hepatocellular. The current trial status is completed. This product is registered under clinical trial identifier NCT03713593. Target conditions include Carcinoma, Hepatocellular.

What happened to similar drugs?

20 of 20 similar drugs in Carcinoma, Hepatocellular were approved

Approved (20) Terminated (1) Active (0)
✅Enfortumab VedotinAstellas PharmaApproved
✅Sonidegib Phosphate CapsulesSun PharmaceuticalApproved
✅LenvatinibEisaiApproved
✅Epirubicin + lipiodolJohnson & JohnsonApproved
✅ApatinibTabletsJiangsu Hengrui MedicineApproved
✅Gefitinib + DocetaxelAstraZenecaApproved
✅Olaparib + BevacizumabAstraZenecaApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03713593Phase 3Completed

Competing Products

20 competing products in Carcinoma, Hepatocellular

See all competitors
ProductCompanyStageHype Score
CD40 agonist mitazalimab in combination with chemotherapyAlligator Bioscience ABPhase 1/2
26
AFM24 + SNK01AffimedPhase 1/2
14
NRC-2694-A + PaclitaxelNatco PharmaPhase 2
42
Sintilimab + Nab paclitaxel + CisplatinCSPC Pharmaceutical Group LimitedPhase 2
35
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + BendamustineLonzaPhase 1
18
Pemetrexed + CarboplatinEli LillyPhase 3
40
PRGN-3005 UltraCAR-T cells + PRGN-3005 UltraCAR-T cellsPrecigenPhase 1
27
Cemiplimab + CetuximabEli LillyPhase 2
42
IMC-1121B (ramucirumab) + Oxaliplatin + Folinic acid + 5-FU + 5-FUEli LillyPhase 2
35
[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359Perspective TherapeuticsPhase 1/2
33
CT-01 + EVEROLIMUSCaptor TherapeuticsPhase 1
26
BB-401Benitec BiopharmaPhase 2
25
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
29
AzenosertibZentalis PharmaceuticalsPhase 2
25
6-Thio-2'-Deoxyguanosine + CemiplimabMAIA BiotechnologyPhase 2
32
6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine aloneMAIA BiotechnologyPhase 3
37
ateganosine + CadonilimabMAIA BiotechnologyPhase 1
26
gemcitabine + carboplatin + cisplatinEli LillyPhase 2
35
CetuximabEli LillyPhase 1
29
Ramucirumab + PaclitaxelEli LillyPhase 2
35